Novel Combination Chemotherapy for Refractory and Recurrent DLBCL

Scientists have identified a novel combination chemotherapy regimen for treating refractory and recurrent diffuse large B-cell lymphoma (DLBCL), a type of cancer. The study, published in Clinical Cancer Research, found that a combination of rapamycin and UCN-01 effectively inhibited DLBCL cell proliferation and induced apoptosis in the majority of lymphoma samples analyzed. The researchers also discovered that the PI3K/Akt/mTOR pathway and cell cycle progression are key targets for DLBCL therapy.

Key Takeaways:

The study analyzed lymphoma samples from 38 cases of primary and recurrent DLBCL using real-time quantitative PCR and immunohistochemistry.
The Farage, Karpas422, Pfeiffer, and Toledo DLBCL cell lines were treated with rapamycin and UCN-01 alone or in combination to assess cell proliferation, apoptosis, and cell cycle progression.
The combination of rapamycin and UCN-01 synergistically inhibited DLBCL cell proliferation by inducing G1 arrest and apoptosis.
RPS6KB1 and CDC2 overexpression is common in DLBCL, and simultaneously targeting their products phospho-p70S6K/p85S6K and cdc2/cdk1 is effective in inhibiting DLBCL proliferation and overcoming drug resistance.
The study suggests that multilevel inhibition of the PI3K/Akt/mTOR pathway and double-block of cell cycle progression are effective strategies for DLBCL therapy.
The researchers concluded that the novel combination chemotherapy regimen may offer a potential treatment option for refractory and recurrent DLBCL patients.

Statistics:

38 lymphoma samples were analyzed in the study.
94% of the lymphomas were strongly positive for phospho-p70S6K and cdc2/cdk1 proteins.
The combination of rapamycin and UCN-01 induced G1 arrest in DLBCL cells.
The study found that RPS6KB1 and CDC2 overexpression is common in DLBCL, affecting approximately 94% of the lymphomas analyzed.

Sources:

M.Y. Zhao et al., "Phospho-p70S6K/p85S6K and cdc2/cdk1 Are Novel Targets for Diffuse Large B-Cell Lymphoma Combination Therapy." Clinical Cancer Research, vol. 15, no. 5 (2009): 1708-1720.
American Association for Cancer Research, Clinical Cancer Research, 615 Chestnut St., 17th Floor, Philadelphia, PA 19106-4404, USA.
University of Maryland, School of Medicine, Department of Pathology, 10 S. Pine St., MSTF 611B, Baltimore, MD 21201, USA.